Product References — Single Donor Human Plasma Whole Blood Derived

Plasma MMP-3: A Novel Biomarker Predicting ARDS Patient Outcomes

Posted by Adam Awdish on

Plasma MMP-3: A Novel Biomarker Predicting ARDS Patient Outcomes

In the quest to enhance patient care in critical conditions, the discovery of predictive biomarkers stands out as a beacon of hope. A recent study published in Respiratory Research by Jones et al., titled "Plasma matrix metalloproteinase-3 predicts mortality in acute respiratory distress syndrome: a biomarker analysis of a randomized controlled trial," presents groundbreaking findings that could revolutionize the management of Acute Respiratory Distress Syndrome (ARDS). The Significance of MMP-3 Matrix metalloproteinase-3 (MMP-3) has emerged from this study as a crucial biomarker capable of predicting mortality among ARDS patients. The research meticulously analyzed plasma levels of MMP-3, uncovering its significant...

Read more →

The Binding Mechanisms of Antibodies to DNA from Healthy Subjects and Patients with Systemic Lupus Erythematosus: The Role of Monogamous Bivalency and Fc Dependence

Posted by Adam Awdish on

The Binding Mechanisms of Antibodies to DNA from Healthy Subjects and Patients with Systemic Lupus Erythematosus: The Role of Monogamous Bivalency and Fc Dependence

Single Donor Human Plasma (Blood Derived) from Innovative Research was used in the following study:   The Binding Mechanisms of Antibodies to DNA from Healthy Subjects and Patients with Systemic Lupus Erythematosus: The Role of Monogamous Bivalency and Fc Dependence Morgan E. Belina, Diane M. Spencer, and David S. Pisetsky ImmunoHorizons February 1, 2022 Antibodies that target DNA (anti-DNA) are a unique subset of antibodies which bind to the structural components of DNA molecules. They were originally observed within the context of systemic lupus erythematosus (SLE), and anti-DNA in SLE appeared to have the ability to bind DNA regardless of...

Read more →

LC-MS/MS Method for Simultaneous Quantification of the First-Line Anti-Tuberculosis Drugs and Six Primary Metabolites in Patient Plasma: Implications for Therapeutic Drug Monitoring

Posted by Adam Awdish on

LC-MS/MS Method for Simultaneous Quantification of the First-Line Anti-Tuberculosis Drugs and Six Primary Metabolites in Patient Plasma: Implications for Therapeutic Drug Monitoring

Single Donor Human Plasma (Blood Derived) from Innovative Research was used in the following study:   LC-MS/MS Method for Simultaneous Quantification of the First-Line Anti-Tuberculosis Drugs and Six Primary Metabolites in Patient Plasma: Implications for Therapeutic Drug Monitoring Agnija Kivrane, Solveiga Grinberga, Eduards Sevostjanovs, Viktorija Igumnova, Ilva Pole, Anda Viksna, Dace Bandere, Alvils Krams, Andra Cirule, Osvalds Pugovics, Renate Ranka Journal of Chromatography B November 15, 2021 Tuberculosis (TB) is an infection caused by an airborne bacteria called Mycobacterium tuberculosis. Despite the advances in treating TB over the years there is still an estimated 10 million new cases around the...

Read more →

Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients is Associated with Underlying Non-Inflamed Tumor Profile

Posted by Adam Awdish on

Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients is Associated with Underlying Non-Inflamed Tumor Profile

Single Donor Human Plasma (Blood Derived) from Innovative Research was used in the following study:   Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients is Associated with Underlying Non-Inflamed Tumor Profile Rania H. Younis, Ioana Ghita, Manar Elnaggar, Risa Chaisuparat, Vasileios Ionas Theofilou, Donita Dyalram, Robert A. Ord, Eduardo Davila, Luke J. Tallon, John C. Papadimitriou, Tonya J. Webb, Søren M. Bentzen, and Joshua E. Lubek Frontiers in Immunology March 11, 2021 Semaphorin 4D (Sema4D) is a glycoprotein that is capable of functioning as both a membrane bound protein or as a cleaved soluble protein (sSema4D),...

Read more →

Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation

Posted by Adam Awdish on

Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation

Single Donor Human Whole Blood, Single Donor Human Plasma (Blood Derived), Single Donor Human Complement Serum, Innovative Grade US Origin Porcine Plasma, and Innovative Grade US Origin Porcine Whole Blood from Innovative Research were used in the following study:   Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation Nuzhat Maisha, Tobias Coombs, and Erin B. Lavik American Chemical Society July 6, 2020 Nanomedicines are often recognized by the innate immune system as a threat, leading to unwanted clearance due to complement activation. This unwanted reaction not only alters the bioavailability of the therapeutic, but can...

Read more →


×